You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 10,213,513

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,213,513

Title:	Treating myelomas
Abstract:	This document provides methods and materials related to treating myelomas. For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., ABRAXANE.RTM./anti-CD38 polypeptide antibody complexes) to treat myelomas are provided.
Inventor(s):	Markovic; Svetomir N. (Rochester, MN), Nevala; Wendy K. (Rochester, MN)
Assignee:	Mayo Foundation for Medical Education and Research (Rochester, MN)
Application Number:	15/030,568
Patent Claims:	1. A method for treating a mammal having myeloma, said method comprising administering to said mammal an effective amount of a composition comprising nanoparticles containing albumin-bound paclitaxel complexed with an anti-CD38 polypeptide antibody, said complexed nanoparticles having an average diameter of less than 1 .mu.m, wherein the effective amount is an amount that treats the myeloma, wherein the effective amount for the anti-CD38 polypeptide antibody is about 5 mg/kg to about 20 mg/kg. 2. The method of claim 1, wherein the anti-CD38 antibody is daratumumab, MOR202 or SAR650984. 3. The method of claim 1, wherein the composition is administered by injection. 4. The method of claim 1, wherein the average diameter of the complexed nanoparticles is from about 0.1 .mu.m to about 0.3 .mu.m. 5. The method of claim 1, wherein the effective amount is between about 50 mg/m.sup.2 to about 150 mg/m.sup.2 of albumin and paclitaxel. 6. The method of claim 1, wherein the mammal is a human. 7. The method of claim 1, wherein the composition further comprises a pharmaceutically acceptable excipient. 8. The method of claim 7, wherein the pharmaceutically acceptable excipient comprises saline, water, lactic acid, mannitol, or a combination thereof. 9. The method of claim 1, wherein the treatment increases the length of progression-free survival in the mammal. 10. The method of claim 1, wherein the amount of the anti-CD38 polypeptide antibody in the composition is about 2 mg/mL. 11. The method of claim 1, wherein the concentration ratio of the nanoparticles to the anti-CD38 polypeptide antibody is 5:2.

Details for Patent 10,213,513

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	DARZALEX	daratumumab	Injection	761036	11/16/2015	⤷ Try a Trial	2034-06-16
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.